Raymond James Financial
IRD

Raymond James Financial’s Opus Genetics IRD Stock Holding History

Raymond James Financial’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.8K Sell
19,508
-1,000
-5% -$3.46K ﹤0.01% 5060
2025
Q4 		$41.2K Sell
20,508
-2,000
-9% -$4.06K ﹤0.01% 5028
2025
Q3 		$37.1K Buy
22,508
+11,000
+96% +$13.7K ﹤0.01% 4854
2025
Q2 		$10.8K Hold
11,508
– – ﹤0.01% 5893
2025
Q1 		$11.3K Sell
11,508
-3,472
-23% -$3.88K ﹤0.01% 4769
2024
Q4 		$17.8K Buy
+14,980
New +$17.2K ﹤0.01% 4734

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Raymond James Financial's IRD Position: Q1 2026 in Review

Raymond James Financial reduced its Opus Genetics (IRD) stake by 4.9% in Q1 2026, selling an estimated $3.46K and leaving 19,508 shares worth $88.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5060.

Raymond James Financial first reported a position in IRD in Q4 2024 and has held it in 6 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Raymond James Financial held 19,508 shares of Opus Genetics worth $88.8K as of Q1 2026.
  • Raymond James Financial sold 1,000 Opus Genetics shares in Q1 2026, an estimated $3.46K.
  • Opus Genetics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5060 holding.
  • Raymond James Financial first reported a position in Opus Genetics in Q4 2024 and has held it in 6 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.